Q1 Earnings Forecast for HRTX Issued By Northland Securities

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Northland Securities cut their Q1 2026 EPS estimates for Heron Therapeutics in a research note issued to investors on Thursday, March 26th. Northland Securities analyst C. Byrnes now expects that the biotechnology company will post earnings of ($0.02) per share for the quarter, down from their previous forecast of ($0.01). The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.13) per share.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01. The business had revenue of $40.59 million during the quarter, compared to the consensus estimate of $39.53 million.

Several other equities analysts have also commented on HRTX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heron Therapeutics in a report on Thursday, January 22nd. HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Heron Therapeutics in a research report on Friday, January 9th. Finally, Zacks Research downgraded Heron Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Thursday, February 26th. Three research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $4.50.

Heron Therapeutics Price Performance

HRTX opened at $0.78 on Monday. The company has a quick ratio of 1.51, a current ratio of 2.48 and a debt-to-equity ratio of 10.59. The company’s 50-day moving average price is $1.13 and its 200 day moving average price is $1.21. Heron Therapeutics has a fifty-two week low of $0.75 and a fifty-two week high of $2.61. The firm has a market cap of $147.76 million, a price-to-earnings ratio of -6.03 and a beta of 1.26.

Institutional Investors Weigh In On Heron Therapeutics

Several large investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. raised its holdings in shares of Heron Therapeutics by 57.0% during the first quarter. Goldman Sachs Group Inc. now owns 1,028,678 shares of the biotechnology company’s stock valued at $2,263,000 after buying an additional 373,518 shares during the last quarter. Geode Capital Management LLC grew its holdings in Heron Therapeutics by 14.6% in the 2nd quarter. Geode Capital Management LLC now owns 3,566,813 shares of the biotechnology company’s stock worth $7,385,000 after buying an additional 453,085 shares in the last quarter. Police & Firemen s Retirement System of New Jersey increased its position in Heron Therapeutics by 53.4% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 38,352 shares of the biotechnology company’s stock valued at $79,000 after acquiring an additional 13,352 shares during the period. Intech Investment Management LLC raised its stake in Heron Therapeutics by 16.9% during the 2nd quarter. Intech Investment Management LLC now owns 94,811 shares of the biotechnology company’s stock valued at $196,000 after acquiring an additional 13,725 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Heron Therapeutics by 36.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 953,080 shares of the biotechnology company’s stock valued at $1,973,000 after acquiring an additional 256,637 shares in the last quarter. Institutional investors and hedge funds own 80.01% of the company’s stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.